Prostate-specific human kallikrein (hK2) as a novel marker for prostate cancer

Charles Y.F. Young, Thomas Seay, Kristine Hogen, M. Cristine Charlesworth, Patrick C. Roche, George G. Klee, Donald J. Tindall

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


BACKGROUND. Although prostate-specific antigen (PSA) has aided significantly in the diagnosis of prostate cancer, more sensitive and accurate assays are needed. Presently, we are developing a sensitive immunoassay for hK2 protein for the detection of prostate cancer. METHODS. Polyclonal and monoclonal antibodies specific for hK2 were produced and used for Western blot analysis and immunohistochemistry for detection of hK2 protein in serum and human tissues. The reverse-transcriptase polymerase chain reaction (RT-PCR) was utilized to detect hK2 mRNA from patient blood samples. RESULTS. Western blot analysis demonstrated that the antibodies used are monospecific for hK2. Immunohistochemistry showed that hK2 is expressed only in prostatic epithelia. An RT-PCR study showed that hK2 mRNA would be a useful candidate for early detection of prostatic micrometastasis. CONCLUSIONS. Monospecific antibodies for hK2 have been developed for detecting hK2 protein. Our studies indicate that hK2 may be a useful marker for prostate cancer.

Original languageEnglish (US)
Pages (from-to)17-24
Number of pages8
Issue numberSUPPL. 7
StatePublished - 1996


  • PSA
  • hK2
  • marker
  • prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Prostate-specific human kallikrein (hK2) as a novel marker for prostate cancer'. Together they form a unique fingerprint.

Cite this